|
US5830698A
(en)
*
|
1997-03-14 |
1998-11-03 |
Idec Pharmaceuticals Corporation |
Method for integrating genes at specific sites in mammalian cells via homologous recombination and vectors for accomplishing the same
|
|
RO120148B1
(ro)
*
|
1997-03-14 |
2005-09-30 |
Idec Pharmaceuticals Corporation |
Sistem vector şi procedeu de inserţie a unui fragment adn, în genomul celulelor de mamifere
|
|
WO1999029902A1
(en)
|
1997-12-08 |
1999-06-17 |
California Institute Of Technology |
Method for creating polynucleotide and polypeptide sequences
|
|
CA2360347C
(en)
|
1998-12-31 |
2013-05-07 |
Chiron Corporation |
Improved expression of hiv polypeptides and production of virus-like particles
|
|
WO2000039304A2
(en)
|
1998-12-31 |
2000-07-06 |
Chiron Corporation |
Polynucleotides encoding antigenic hiv type c polypeptides, polypeptides and uses thereof
|
|
GB9912965D0
(en)
*
|
1999-06-03 |
1999-08-04 |
Oxford Biomedica Ltd |
In vivo selection method
|
|
US6316253B1
(en)
|
1999-11-01 |
2001-11-13 |
Chiron Corporation |
Expression vectors, transfection systems, and method of use thereof
|
|
DK1297170T3
(en)
*
|
2000-06-23 |
2016-03-14 |
Novozymes As |
A process for stable chromosomal integration of multiple copies of the genes
|
|
EP2412242A3
(en)
|
2001-07-05 |
2012-06-13 |
Novartis Vaccines and Diagnostics, Inc. |
Polynucleotides encoding antigenic HIV Type C polypeptides, polypeptides and uses thereof
|
|
US20030170614A1
(en)
|
2001-08-31 |
2003-09-11 |
Megede Jan Zur |
Polynucleotides encoding antigenic HIV type B polypeptides, polypeptides and uses thereof
|
|
HUP0402164A3
(en)
|
2001-11-16 |
2010-01-28 |
Biogen Idec Inc |
Polycistronic expression of antibodies
|
|
US7164056B2
(en)
*
|
2002-05-03 |
2007-01-16 |
Pioneer Hi-Bred International, Inc. |
Gene targeting using replicating DNA molecules
|
|
PT1523496E
(pt)
|
2002-07-18 |
2011-09-29 |
Merus B V |
Produção de misturas de anticorpos de forma recombinante
|
|
USRE47770E1
(en)
|
2002-07-18 |
2019-12-17 |
Merus N.V. |
Recombinant production of mixtures of antibodies
|
|
US20040170614A1
(en)
*
|
2002-10-30 |
2004-09-02 |
Gail Bishop |
Somatic cell gene targeting vectors and methods of use thereof
|
|
EA013225B1
(ru)
*
|
2003-01-07 |
2010-04-30 |
Симфоген А/С |
Способ получения линии клеток, продуцирующей рекомбинантный поликлональный белок, способ получения поликлонального белка, линия клеток, продуцирующая рекомбинантный поликлональный белок, библиотека векторов, популяция клеток
|
|
DE10303937A1
(de)
*
|
2003-01-31 |
2004-08-12 |
Icon Genetics Ag |
Pflanzentransformation mit Assemblierung einer gewünschten Sequenz in Vivo
|
|
ATE426672T1
(de)
*
|
2003-01-31 |
2009-04-15 |
Icon Genetics Gmbh |
Pflanzentransformation mit in-vivo-zusammenbau einer eigenschaft
|
|
WO2004085648A2
(en)
|
2003-03-19 |
2004-10-07 |
Biogen Idec Ma Inc. |
Nogo receptor binding protein
|
|
TWI353991B
(en)
|
2003-05-06 |
2011-12-11 |
Syntonix Pharmaceuticals Inc |
Immunoglobulin chimeric monomer-dimer hybrids
|
|
JP5416338B2
(ja)
*
|
2003-05-09 |
2014-02-12 |
デューク ユニバーシティ |
Ｃｄ２０特異的抗体およびその使用方法
|
|
US20100069614A1
(en)
|
2008-06-27 |
2010-03-18 |
Merus B.V. |
Antibody producing non-human mammals
|
|
EP1639009B1
(en)
|
2003-05-30 |
2013-02-27 |
Merus B.V. |
Fab library for the preparation of a mixture of antibodies
|
|
AU2004252170B2
(en)
*
|
2003-06-27 |
2011-01-27 |
Biogen Ma Inc. |
Use of hydrophobic-interaction-chromatography or hinge-region modifications for the production of homogeneous antibody-solutions
|
|
ES2374526T3
(es)
|
2003-09-04 |
2012-02-17 |
Medarex, Inc. |
Vector de expresión.
|
|
US8030833B2
(en)
*
|
2003-09-19 |
2011-10-04 |
The Board Of Trustees Of The University Of Illinois |
Electron emission device incorporating free standing monocrystalline nanowires
|
|
US7344753B2
(en)
*
|
2003-09-19 |
2008-03-18 |
The Board Of Trustees Of The University Of Illinois |
Nanostructures including a metal
|
|
US7935862B2
(en)
*
|
2003-12-02 |
2011-05-03 |
Syngenta Participations Ag |
Targeted integration and stacking of DNA through homologous recombination
|
|
CA2554054C
(en)
|
2004-01-20 |
2013-06-04 |
Merus B.V. |
Mixtures of binding proteins
|
|
BRPI0512500A
(pt)
|
2004-06-24 |
2008-03-11 |
Biogen Idec Inc |
tratamento ou condições envolvendo desmielinação
|
|
EP2053408B1
(en)
|
2004-07-20 |
2012-03-07 |
Symphogen A/S |
A procedure for structural characterization of a recombinant polyclonal protein or a polyclonal cell line
|
|
EP2329714A1
(en)
|
2004-08-03 |
2011-06-08 |
Biogen Idec MA Inc. |
Influence of TAJ in the neuronal functions
|
|
FR2879204B1
(fr)
|
2004-12-15 |
2007-02-16 |
Lab Francais Du Fractionnement |
Anticorps cytotoxique dirige contre les proliferations hematopoietiques lymphoides de type b.
|
|
KR20070100346A
(ko)
|
2005-01-05 |
2007-10-10 |
바이오겐 아이덱 엠에이 인코포레이티드 |
크립토 결합 분자
|
|
CN100381573C
(zh)
*
|
2005-04-14 |
2008-04-16 |
北京天广实生物技术有限公司 |
快速构建目标基因高表达的哺乳动物细胞株的体系和方法
|
|
RS53058B
(sr)
|
2005-07-08 |
2014-04-30 |
Biogen Idec Ma Inc. |
Sp35 antitela i njihova primena
|
|
NZ565711A
(en)
*
|
2005-08-09 |
2011-10-28 |
Revivicor Inc |
Transgenic ungulates expressing a porcine CTLA4 peptide fused to an immunoglobulin
|
|
JP2009517340A
(ja)
|
2005-11-04 |
2009-04-30 |
バイオジェン・アイデック・エムエイ・インコーポレイテッド |
ドーパミン作動性ニューロンの神経突起成長および生存を促進するための方法
|
|
NZ569428A
(en)
|
2005-12-02 |
2012-11-30 |
Biogen Idec Inc |
Treatment of conditions involving demyelination with a Sp35 antagonist
|
|
US20070136826A1
(en)
*
|
2005-12-02 |
2007-06-14 |
Biogen Idec Inc. |
Anti-mouse CD20 antibodies and uses thereof
|
|
CN103215293B
(zh)
|
2006-01-27 |
2015-10-28 |
比奥根Ma公司 |
Nogo受体拮抗剂
|
|
SI2436696T1
(sl)
|
2007-01-05 |
2017-10-30 |
University Of Zurich |
Anti-beta-amiloidno protitelo in načini njegove uporabe
|
|
CA2674603C
(en)
|
2007-01-09 |
2016-03-29 |
Biogen Idec Ma Inc. |
Sp35 antibodies and uses thereof
|
|
US8128926B2
(en)
|
2007-01-09 |
2012-03-06 |
Biogen Idec Ma Inc. |
Sp35 antibodies and uses thereof
|
|
EA017403B1
(ru)
|
2007-02-02 |
2012-12-28 |
Байоджен Айдек Эмэй Инк. |
Использование семафорина 6а в качестве промотора миелинизации и дифференцировки олигодендроцитов
|
|
CA2701189C
(en)
*
|
2007-10-11 |
2017-05-16 |
Biogen Idec Ma Inc. |
Methods for treating pressure induced optic neuropathy, preventing neuronal degeneration and promoting neuronal cell survival via administration of lingo-1 antagonists and trkb agonists
|
|
WO2009061500A1
(en)
*
|
2007-11-08 |
2009-05-14 |
Biogen Idec Ma Inc. |
Use of lingo-4 antagonists in the treatment of conditions involving demyelination
|
|
CA2708776A1
(en)
*
|
2007-12-10 |
2009-06-18 |
Aliva Biopharmaceuticals, Inc. |
Methods for sequential replacement of targeted region by homologous recombination
|
|
DK2982695T3
(da)
|
2008-07-09 |
2019-05-13 |
Biogen Ma Inc |
Sammensætninger, der omfatter antistoffer mod lingo eller fragmenter deraf
|
|
KR102362774B1
(ko)
|
2008-09-30 |
2022-02-15 |
아블렉시스, 엘엘씨 |
키메라 항체의 제조를 위한 인간 이외의 포유동물
|
|
EA030826B1
(ru)
|
2008-12-19 |
2018-10-31 |
Панима Фармасьютикалз Аг |
ЧЕЛОВЕЧЕСКИЕ АУТОАНТИТЕЛА ПРОТИВ α-СИНУКЛЕИНА
|
|
EP2382238A1
(en)
|
2008-12-31 |
2011-11-02 |
Biogen Idec MA Inc. |
Anti-lymphotoxin antibodies
|
|
CA2756186A1
(en)
|
2009-03-24 |
2010-09-30 |
Teva Biopharmaceuticals Usa, Inc. |
Humanized antibodies against light and uses thereof
|
|
JP4998814B2
(ja)
|
2009-10-01 |
2012-08-15 |
Ｔｏｔｏ株式会社 |
Ｄｎａ構築物およびそれを用いた組み換えｃｈｏ細胞の製造方法
|
|
ES2641920T3
(es)
|
2010-03-31 |
2017-11-14 |
Ablexis, Llc |
Ingeniería genética de animales no humanos para la producción de anticuerpos quiméricos
|
|
SG184903A1
(en)
*
|
2010-04-30 |
2012-11-29 |
Temasek Life Sciences Lab Ltd |
Fragment switch: a reverse genetic approach
|
|
EA201291482A1
(ru)
|
2010-07-09 |
2013-10-30 |
Байоджен Айдек Хемофилия Инк. |
Химерные факторы коагуляции
|
|
PT2627672T
(pt)
|
2010-10-11 |
2018-11-16 |
Univ Zuerich |
Anticorpos anti-tau humanos
|
|
DK2640743T3
(en)
|
2010-11-16 |
2017-01-23 |
Excelimmune Inc |
PROCEDURES FOR THE PREPARATION OF RECOMBINANT PROTEINS
|
|
JP5209693B2
(ja)
*
|
2010-12-10 |
2013-06-12 |
ロンザ・バイオロジクス・ピーエルシー |
Ｃｈｏ細胞において組換えタンパク質を発現する方法
|
|
JP6067575B2
(ja)
|
2010-12-17 |
2017-01-25 |
ニューリミューン ホールディング エイジー |
ヒト抗ｓｏｄ１抗体
|
|
ES2699801T3
(es)
|
2011-06-23 |
2019-02-12 |
Biogen Int Neuroscience Gmbh |
Moléculas de unión anti-alfa sinucleína
|
|
US9738707B2
(en)
|
2011-07-15 |
2017-08-22 |
Biogen Ma Inc. |
Heterodimeric Fc regions, binding molecules comprising same, and methods relating thereto
|
|
US9175072B2
(en)
|
2011-12-22 |
2015-11-03 |
Elwha Llc |
Compositions and methods including recombinant B lymphocyte cell line including an exogenously incorporated nucleic acid expressing an exogenous membrane immunoglobulin reactive to a first antigen and including an endogenous gene expressing an endogenous secreted immunoglobulin reactive to a second antigen
|
|
US10745468B2
(en)
|
2011-12-22 |
2020-08-18 |
Kota Biotherapeutics, Llc |
Compositions and methods for modified B cells expressing reassigned biological agents
|
|
US8962315B2
(en)
|
2011-12-22 |
2015-02-24 |
Elwha Llc |
Compositions and methods including recombinant B lymphocyte cell line including at least one endogenous gene expressing at least one endogenous membrane immunoglobulin reactive to a first antigen and including at least one exogenously incorporated nucleic acid expressing at least one exogenous secreted immunoglobulin reactive to a second antigen
|
|
US10233424B2
(en)
|
2011-12-22 |
2019-03-19 |
Elwha Llc |
Compositions and methods including cytotoxic B lymphocyte cell line expressing exogenous membrane immunoglobulin different from secreted immunoglobulin
|
|
ES2740749T3
(es)
|
2012-04-20 |
2020-02-06 |
Merus Nv |
Métodos y medios para la producción de moléculas heterodiméricas similares a Ig
|
|
KR101904508B1
(ko)
|
2012-04-25 |
2018-10-04 |
리제너론 파마슈티칼스 인코포레이티드 |
큰 표적화 벡터를 사용한 뉴클레아제-중재된 표적화
|
|
US10174331B2
(en)
|
2012-05-07 |
2019-01-08 |
Sangamo Therapeutics, Inc. |
Methods and compositions for nuclease-mediated targeted integration of transgenes
|
|
EP2849787A4
(en)
|
2012-05-14 |
2016-06-15 |
Biogen Ma Inc |
LINGO-2 ANTAGONISTS FOR THE TREATMENT OF DISEASES INVOLVING ENGINE NEURONS
|
|
JP2015525222A
(ja)
|
2012-06-08 |
2015-09-03 |
バイオジェン・エムエイ・インコーポレイテッドＢｉｏｇｅｎ ＭＡ Ｉｎｃ． |
キメラ性凝固因子
|
|
MX2015004436A
(es)
|
2012-10-09 |
2015-06-24 |
Biogen Idec Inc |
Tratamientos conjuntos y usos para tratar trastornos desmielinizantes.
|
|
AU2013361107B2
(en)
|
2012-12-21 |
2018-08-23 |
Biogen International Neuroscience Gmbh |
Human anti-tau antibodies
|
|
US9771413B2
(en)
|
2012-12-31 |
2017-09-26 |
Neurimmune Holding Ag |
Recombinant human antibodies for therapy and prevention of polyomavirus-related diseases
|
|
PL2956477T5
(pl)
|
2013-02-15 |
2024-05-27 |
Bioverativ Therapeutics Inc. |
Zoptymalizowany gen czynnika viii
|
|
SG10201707600XA
(en)
|
2013-03-15 |
2017-11-29 |
Biogen Ma Inc |
Factor ix polypeptide formulations
|
|
US11008561B2
(en)
|
2014-06-30 |
2021-05-18 |
Bioverativ Therapeutics Inc. |
Optimized factor IX gene
|
|
CN107074937B
(zh)
|
2014-07-29 |
2021-07-27 |
神经免疫控股公司 |
人源抗亨廷顿蛋白(htt)抗体及其用途
|
|
AU2015326911C1
(en)
|
2014-09-30 |
2025-12-18 |
Neurimmune Holding Ag |
Human-derived anti-dipeptide repeats (DPRs) antibody
|
|
MA40835A
(fr)
|
2014-10-23 |
2017-08-29 |
Biogen Ma Inc |
Anticorps anti-gpiib/iiia et leurs utilisations
|
|
MA40861A
(fr)
|
2014-10-31 |
2017-09-05 |
Biogen Ma Inc |
Anticorps anti-glycoprotéines iib/iiia
|
|
MX2017009038A
(es)
|
2015-01-08 |
2017-10-25 |
Biogen Ma Inc |
Antagonistas de proteina 1 de interacción con el receptor de nogo que contiene el dominio de inmunoglobulina y repeticiones ricas en leucina (lingo-1) y usos para el tratamiento de trastornos desmielinizantes.
|
|
CN106191040B
(zh)
*
|
2015-04-30 |
2021-09-14 |
杭州菁因康生物科技有限公司 |
基因打靶方法
|
|
IL257231B
(en)
|
2015-08-03 |
2022-09-01 |
Bioverativ Therapeutics Inc |
Factor ix fusion proteins and methods of making and using same
|
|
RS63548B1
(sr)
|
2016-02-01 |
2022-09-30 |
Bioverativ Therapeutics Inc |
Optimizovani geni faktora viii
|
|
WO2017214376A1
(en)
|
2016-06-10 |
2017-12-14 |
Elwha Llc |
Compositions and methods including b lymphocyte cell line expressing membrane immunoglobulin different from secreted immunoglobulin and cytolytic function
|
|
JP2018035137A
(ja)
|
2016-07-13 |
2018-03-08 |
マブイミューン ダイアグノスティックス エイジーＭａｂｉｍｍｕｎｅ Ｄｉａｇｎｏｓｔｉｃｓ Ａｇ |
新規な抗線維芽細胞活性化タンパク質（ｆａｐ）結合薬剤およびその使用
|
|
MA45668A
(fr)
|
2016-07-13 |
2019-05-22 |
Biogen Ma Inc |
Schémas posologiques d'antagonistes de lingo-1 et leurs utilisations pour le traitement de troubles de démyélinisation
|
|
CA3044838A1
(en)
|
2016-12-02 |
2018-06-07 |
Bioverativ Therapeutics Inc. |
Methods of inducing immune tolerance to clotting factors
|
|
CN110520150A
(zh)
|
2016-12-02 |
2019-11-29 |
比奥维拉迪维治疗股份有限公司 |
使用嵌合凝血因子治疗血友病性关节病的方法
|
|
EA201991768A1
(ru)
|
2017-01-31 |
2020-01-22 |
Байоверетив Терапьютикс Инк. |
Слитые белки на основе фактора ix и способы их получения и пути применения
|
|
KR20250040746A
(ko)
|
2017-08-09 |
2025-03-24 |
바이오버라티브 테라퓨틱스 인크. |
핵산 분자 및 이의 용도
|
|
BR112020018709A2
(pt)
|
2018-03-28 |
2021-01-05 |
Bristol-Myers Squibb Company |
Proteínas de fusão do receptor alfa de interleucina-2/interleucina-2 e métodos de uso
|
|
WO2019210054A1
(en)
|
2018-04-27 |
2019-10-31 |
Biogen Ma Inc. |
Human-derived anti-(poly-ga) dipeptide repeat (dpr) antibody
|
|
LT3793588T
(lt)
|
2018-05-18 |
2025-06-25 |
Bioverativ Therapeutics Inc. |
Hemofilijos a gydymo būdai
|
|
KR102848349B1
(ko)
|
2018-06-04 |
2025-08-21 |
바이오젠 엠에이 인코포레이티드 |
감소된 효과기 기능을 갖는 항-ｖｌａ-4 항체
|
|
CN110607326B
(zh)
*
|
2018-06-15 |
2022-11-29 |
江苏省农业科学院 |
非强启动式的外源基因表达法及其在具有毒性的目标蛋白表达中的应用
|
|
JP7602454B2
(ja)
|
2018-08-09 |
2024-12-18 |
バイオベラティブ セラピューティクス インコーポレイテッド |
核酸分子及び非ウイルス遺伝子治療のためのそれらの使用
|
|
JP7549582B2
(ja)
*
|
2018-10-01 |
2024-09-11 |
ロンザ リミテッド |
予測可能かつ安定な導入遺伝子発現を有するｓｓｉ細胞および形成の方法
|
|
SG11202108560RA
(en)
|
2019-02-13 |
2021-09-29 |
Brigham & Womens Hospital Inc |
Anti-peripheral lymph node addressin antibodies and uses thereof
|
|
US12403164B2
(en)
|
2019-09-30 |
2025-09-02 |
Bioverativ Therapeutics Inc. |
Lentiviral vector formulations
|
|
JP2023516028A
(ja)
|
2020-02-28 |
2023-04-17 |
ザ ブリガム アンド ウィメンズ ホスピタル インコーポレイテッド |
多重特異性抗体を介したトランスフォーミング増殖因子ベータスーパーファミリーシグナル伝達の選択的調節
|
|
BR112022026127A2
(pt)
|
2020-06-24 |
2023-01-17 |
Bioverativ Therapeutics Inc |
Métodos para remoção de fator viii livre de preparações de vetores lentivirais modificados para expressar referida proteína
|
|
WO2023028455A1
(en)
|
2021-08-23 |
2023-03-02 |
Bioverativ Therapeutics Inc. |
Closed-end dna production with inverted terminal repeat sequences
|
|
TW202323274A
(zh)
|
2021-08-23 |
2023-06-16 |
美商百歐維拉提夫治療公司 |
優化因子viii基因
|
|
AU2022355088A1
(en)
|
2021-09-30 |
2024-05-16 |
Bioverativ Therapeutics Inc. |
Nucleic acids encoding factor viii polypeptides with reduced immunogenicity
|
|
WO2025104243A1
(en)
|
2023-11-15 |
2025-05-22 |
Neurimmune Ag |
Anti-transthyretin antibody, compositions comprising said antibody and methods for treating or preventing transthyretin-mediated amyloidosis
|